Press release |

The appeal – filed by six organisations – states that the EPO should revoke Gilead’s patent on key hepatitis C drug sofosbuvir because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.

Read more
Photograph by Peter Bauza

Latest news

What good is a breakthrough medicine if the people who need it can't afford it?